Related Experiment Video
Updated: Jun 12, 2025
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
40.6K
Inhaled budesonide and pulmonary sarcoidosis revisited
Olof Selroos1, Ralph Brattsand1
1Independent researcher.
Summary
Inhaled corticosteroids (ICS), particularly budesonide (BUD), show some efficacy in pulmonary sarcoidosis maintenance therapy. Further research may yield ICS with better systemic risk profiles for treating lung diseases.
Area of Science:
- Pulmonology
- Pharmacology
- Immunology
Background:
- Pulmonary sarcoidosis is a complex inflammatory disease affecting the lungs.
- Inhaled corticosteroids (ICS) have been investigated for treating pulmonary sarcoidosis, with limited but notable findings.
- Budesonide (BUD) has shown particular promise in specific treatment contexts.
Purpose of the Study:
- To review and summarize the clinical evidence for ICS use in pulmonary sarcoidosis.
- To explore the pharmacokinetic and pharmacodynamic mechanisms underlying budesonide's efficacy.
- To identify potential future directions for ICS-based therapies in sarcoidosis.
Main Methods:
- Systematic review of controlled clinical studies involving ICS in pulmonary sarcoidosis.
- Analysis of pharmacokinetic data for inhaled budesonide, including systemic absorption and local transformation.
- Comparison of budesonide's efficacy with other ICS and systemic corticosteroids.
Main Results:
- Controlled studies show some efficacy for ICS, predominantly budesonide (BUD), in pulmonary sarcoidosis.
- BUD's effectiveness is mainly observed in maintenance therapy after initial systemic corticosteroid treatment or for relapses.
- Proposed mechanisms for BUD's efficacy involve rapid systemic absorption and prolonged local anti-inflammatory activity via BUD-oleate formation.
Conclusions:
- Current ICS, including BUD, are not broadly recommended for routine sarcoidosis treatment.
- Budesonide's pharmacokinetic profile offers insights for developing future ICS with optimized airway versus systemic activity.
- Further research could lead to novel ICS that reduce reliance on oral corticosteroids for pulmonary diseases.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
186
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
186
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
227
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
227
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
238
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
238
01:23Inhaled Medications
240
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
240